This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Albireo Pharma 미래 성장
Future 기준 확인 2/6
주요 정보
62.9%
수익 성장률
61.4%
EPS 성장률
Biotechs 수익 성장 | 24.1% |
매출 성장률 | 51.1% |
향후 자기자본 수익 률 | n/a |
애널리스트 커버리지 | Good |
마지막 업데이트 | 24 Feb 2023 |
최근 미래 성장 업데이트
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2025 | 248 | -5 | N/A | N/A | 5 |
12/31/2024 | 128 | -102 | N/A | N/A | 5 |
12/31/2023 | 61 | -144 | N/A | N/A | 7 |
12/31/2022 | 35 | -159 | N/A | N/A | 7 |
9/30/2022 | 57 | -131 | -116 | -115 | N/A |
6/30/2022 | 51 | -36 | -114 | -113 | N/A |
3/31/2022 | 45 | -33 | -109 | -108 | N/A |
12/31/2021 | 41 | -34 | -108 | -108 | N/A |
9/30/2021 | 11 | -48 | -122 | -122 | N/A |
6/30/2021 | 9 | -136 | -121 | -120 | N/A |
3/31/2021 | 9 | -120 | -112 | -112 | N/A |
12/31/2020 | 8 | -108 | -101 | -101 | N/A |
9/30/2020 | 12 | -90 | -85 | -85 | N/A |
6/30/2020 | 11 | -82 | -73 | -73 | N/A |
3/31/2020 | 11 | -78 | -64 | -63 | N/A |
12/31/2019 | 10 | -63 | -53 | -53 | N/A |
9/30/2019 | 4 | -71 | -51 | -51 | N/A |
6/30/2019 | 3 | -63 | -47 | -47 | N/A |
3/31/2019 | 2 | -61 | -41 | -41 | N/A |
12/31/2018 | 13 | -46 | -27 | -27 | N/A |
9/30/2018 | 12 | -35 | -25 | -25 | N/A |
6/30/2018 | 12 | -28 | -20 | -20 | N/A |
3/31/2018 | 11 | -19 | -18 | -18 | N/A |
12/31/2017 | 0 | -24 | -28 | -28 | N/A |
9/30/2017 | 3 | -31 | -26 | -26 | N/A |
6/30/2017 | 3 | -28 | -25 | -25 | N/A |
3/31/2017 | 11 | -20 | -15 | -15 | N/A |
12/31/2016 | 11 | -16 | -9 | -9 | N/A |
9/30/2016 | 13 | -5 | -1 | -1 | N/A |
6/30/2016 | 13 | -4 | N/A | 1 | N/A |
3/31/2016 | 5 | -8 | N/A | -5 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: ALBO is forecast to remain unprofitable over the next 3 years.
수익 vs 시장: ALBO is forecast to remain unprofitable over the next 3 years.
고성장 수익: ALBO is forecast to remain unprofitable over the next 3 years.
수익 대 시장: ALBO's revenue (51.1% per year) is forecast to grow faster than the US market (6.9% per year).
고성장 수익: ALBO's revenue (51.1% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time